Symbiotec Pharmalab's IPO is analyzed, with a PE ratio around 50 and PB ratio around 5 considered competitive, suggesting potential listing gains but requiring further market evaluation for long-term prospects.
Source Post
Symbiotec Pharmalab IPO | Analysis | GMP | Review
Aug 21, 2026
This video analyzes the Symbiotec Pharmalab IPO, scheduled from August 24-27 with a price band of ₹988. The IPO is worth ₹1757 crore, but only ₹150 crore will go to the company, with the rest from promoters and existing investors like Rowe Investments and India Business Excellence Fund III exiting. The company manufactures APIs via fermentation, complex injectables, and offers CDMO services. While revenue has grown, profit growth is hampered by interest and employee costs, which the IPO proceeds will address by repaying debt. The valuation, with a PE ratio around 50 and PB ratio around 5, is considered competitive compared to peers, suggesting potential listing gains, but long-term prospects require further market evaluation.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.